Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Lisata Therapeutics, Inc.

< Previous 1 2 Next >
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Present at BIO CEO & Investor Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Present at NobleCon19 Investor Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces Participation in Upcoming Conferences in November
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Tickers LSTA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.